Proving the Business Case for the Internet of Things

Apple app could track eye disease

Steve Rogerson
May 2, 2018
 
An app aims to find out whether Apple smartphones are good enough to track eye diseases. Swiss firm Novartis has launched the FocalView app, an ophthalmic digital research platform created with Apple ResearchKit.
 
FocalView aims to let researchers track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routine of patients, the app aims to reduce barriers to participation, leading to a more nuanced understanding of ophthalmic diseases and potentially accelerating the development of novel treatments.
 
Data capture in traditional ophthalmic clinical trials can be inflexible and infrequent, making it difficult for researchers to monitor patients' disease activity and capture real-world patient experiences. FocalView could help patients complete various assessments, gaining feedback on their visual function, including any changes over time. At the same time, the app could provide researchers with a greater volume of real-world, patient-reported data, creating more flexible and accessible clinical trial designs.
 
"Because patients with eye diseases are often not as mobile, FocalView has the potential to offer tremendous benefit for the ophthalmic community and for researchers looking to develop better treatments for these patients," said Mark Bullimore, medical advisor for the creation of FocalView and dean of the Southern California College of Optometry at Marshall B Ketchum University. "Collating validated patient-reported outcomes in clinical trial research is no longer a nice-to-have. This kind of data is fast becoming a critical element of research and development, because it offers a better reflection of real-world patient experiences, fosters better patient compliance and provides researchers with richer and more accurate data points."
 
FocalView will be tested in a prospective, non-interventional study to evaluate the app's efficacy and usability in assessing visual function. These measurements include visual acuity and contrast sensitivity. Researchers will in turn assess ease of use, level of enrolment and the ability to obtain important documentation for future clinical trial research, such as informed consent. In the next phase, the app will be validated against traditional visual testing that takes place within conventional clinical settings.
 
"Optimising digital technology in research and development, particularly in ophthalmic disease, could have a marked impact on the quality of the data we capture," said Bertrand Bodson, Novartis chief digital officer. "We believe apps like FocalView, which we've made freely available to the research community on an open-source platform, can help accelerate the development of treatments and bring them to the patients who need them most."
 
FocalView is now available for download from the App Store in the USA. Consent to contribute to research data will be required before a user can interact with the tool. Novartis is planning to launch in additional markets in the future.
 
Novartis is an ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products.
 
Located in New Jersey, Novartis Pharmaceuticals is an affiliate of Novartis, which provides healthcare products that address the evolving needs of patients and societies. Headquartered in Switzerland, Novartis offers a portfolio to meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. In 2017, the group achieved net sales of US$49.1bn, while R&D throughout the group amounted to about $9.0bn. Group companies employ 124,000 full-time-equivalent associates.